Following on from information provided to NICE by the company in June 2004 the appraisal of New pharmaceutical treatments for non-Alzheimer dementias was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 380 |
| Referral date | 01 March 2003 |
| Topic area |
|
Provisional Schedule
| Information meeting with consultees: | 25 March 2004 |
| Closing date for invited submissions / evidence submission: | 03 June 2004 |
| Final scope published: | February 2004 |
| 1st appraisal committee meeting: | 01 January 2100 |
| 2nd appraisal committee meeting: | 25 January 2005 |
Project Team
| Assessment Group / Evidence Review Group: | Southampton Health Technology Assessment Centre (SHTAC), University of Southampton |
| Communications manager: | Phil Ranson |
| Executive Lead: | Andrew Dillon |
| Project manager: | Alana Miller |
| Technical Lead: | Alastair Fischer |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 28 December 2022 | Discontinued. Following on from information provided to NICE by the company in June 2004 the appraisal of New pharmaceutical treatments for non-Alzheimer dementias was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 10 February 2004 | Date of Information Meeting for Consultees added. |
| 12 March 2004 | Expected date of issue amended to May 2005. |
| 11 June 2004 | This appraisal has now been halted following confirmation received by the Institute from the manufacturers that they have withdrawn the application to extend the license of donepezil within the European Union to include the treatment of vascular dementia while further data is obtained. The Institute will continue to monitor the progress of marketing authorisation of interventions for non-Alzheimer dementia and will contact consultees and commentators at such time as may be appropriate to resume the appraisal. |
For further information on our processes and methods, please see our CHTE processes and methods manual